
Immunocore Holdings (IMCR) Stock Forecast & Price Target
Immunocore Holdings (IMCR) Analyst Ratings
Bulls say
Immunocore Holdings is well positioned to capture a large portion of the market for metastatic uveal melanoma, as KIMMTRAK has been shown to significantly improve overall survival compared to other treatments. Additionally, the company's deep pipeline of drug candidates in various therapeutic areas provide potential for further revenue growth in the future. With a strong commercial base and potential expansions into new markets and indications, Immunocore has a positive outlook for its stock performance.
Bears say
Immunocore Holdings is a commercial-stage biotechnology company with a deep pipeline in multiple therapeutic areas. However, due to unproven clinical benefit and the need for additional funding, there is a potential downside of 5% to the company's base case. In addition, there is strong competition in solid tumor indications and no guarantee of success for the company's early stage programs. Thus, a negative outlook is justified given the uncertainty surrounding Immunocore's future prospects.
This aggregate rating is based on analysts' research of Immunocore Holdings and is not a guaranteed prediction by Public.com or investment advice.
Immunocore Holdings (IMCR) Analyst Forecast & Price Prediction
Start investing in Immunocore Holdings (IMCR)
Order type
Buy in
Order amount
Est. shares
0 shares